Skip to main content
. Author manuscript; available in PMC: 2009 May 7.
Published in final edited form as: Oncogene. 2008 Aug 11;27(52):6635–6645. doi: 10.1038/onc.2008.262

Figure 3.

Figure 3

Inhibition of the p38 MAP kinase pathway leads to mitotic defects. (a, b). HeLa cells were synchronized with the double thymidine block, released for 6 h, treated with SB203580 for additional 6 h and stained with a phospho-H3 antibody. Scale bar, 5 µm. (c) Histogram quantifying the chromosome lagging phenotype after SB203580 treatment. (d) Cells were synchronized with the double thymidine block, released for 8 h, treated with SB203580 for additional 2, 4 or 6 h, and stained with a phospho-H3 antibody.